|
Jul 25
|
Update: Lyell Immunopharma Shares Rise on Plan to Raise Up to $100 Million in Private Placement
|
|
Jul 25
|
Lyell Immunopharma to Raise $100 Million in Private Placement; Shares Rise Pre-Bell
|
|
Jul 25
|
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
|
|
Jun 23
|
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
|
|
Jun 18
|
Lyell reports new clinical data from trial of large B-cell lymphoma therapy
|
|
Jun 17
|
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
|
|
Jun 9
|
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
|
|
Apr 15
|
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
|
|
Dec 31
|
After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)
|
|
Dec 30
|
After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)
|
|
Oct 4
|
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
|
|
Aug 7
|
Lyell Immunopharma: Q2 Earnings Snapshot
|
|
Aug 7
|
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
|
|
Jun 26
|
Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial
|
|
Jun 26
|
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
|
|
May 7
|
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
|
|
May 7
|
Lyell Immunopharma First Quarter 2024 Earnings: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023)
|
|
May 6
|
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
|
|
Mar 17
|
Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) market cap decline of US$89m may not have as much of an impact on institutional owners after a year of 1.4% returns
|
|
Mar 7
|
Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know
|